Literature DB >> 18558585

Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma.

M Santisteban1, J L Pérez-Gracia, J Ceballos, I Vivas, J García-Foncillas.   

Abstract

We report a case of hormone-refractory prostate cancer (HRPC) treated with oxaliplatin plus gemcitabine in a third-line schedule after liver progression, with an excellent clinical, biochemical and radiological response and with an acceptable tolerance. Prior chemotherapy regimens included docetaxel plus estramustine and oral etoposide. To our knowledge, this is the first report that shows this approach in an HRPC patient.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18558585     DOI： 10.1007/s12094-008-0214-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


  6 in total

1.  [Neuroendocrine carcinoma of the prostate effectively treated by cisplatin and irinotecan--a case report].

Authors:  Shogo Inoue; Kiyotaka Oka; Teruo Araki; Akira Yano; Takatoshi Tacho; Motohiro Fujii; Kuniharu Kimoto; Michiyasu Murakami; Yumi Ohshiro
Journal:  Gan To Kagaku Ryoho       Date:  2007-08

2.  [Short-term efficacy of combined chemotherapy of gemcitabine and cisplatin on advanced hormone refractory prostate cancer].

Authors:  Zi-Ke Qin; Guang-Wei Yang; Fang-Jian Zhou; Hui Han; Zhuo-Wei Liu; Ning-Ning Zhou; Zhi-Gang Wu
Journal:  Ai Zheng       Date:  2004-12

3.  Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer.

Authors:  Giuseppe Di Lorenzo; Riccardo Autorino; Mario Giuliano; Emilio Morelli; Antonio Giordano; Giorgio Napodano; Aniello Russo; Giuseppe Benincasa; Massimino D'Armiento; Vincenzo Altieri; Sabino De Placido
Journal:  Urology       Date:  2007-02       Impact factor: 2.649

4.  Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients.

Authors:  J P Droz; X Muracciole; N Mottet; M Ould Kaci; J M Vannetzel; N Albin; S Culine; J-M Rodier; J-L Misset; S Mackenzie; E Cvitkovic; G Benoit
Journal:  Ann Oncol       Date:  2003-08       Impact factor: 32.976

5.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245
  6 in total
  1 in total

1.  Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.

Authors:  J-L Lee; J-H Ahn; M K Choi; Y Kim; S-W Hong; K-H Lee; I-G Jeong; C Song; B-S Hong; J H Hong; H Ahn
Journal:  Br J Cancer       Date:  2014-04-15       Impact factor: 7.640
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.